Trinity Biotech PLC TRIB
Biotechnology: In Vitro & In Vivo Diagnostic Substances · IPO 1992 · data as of November 13, 2026
Trinity Biotech PLC (TRIB) is a healthcare company listed in the US with a market value of about $5M. In fiscal year 2025 it had revenue of $44M and net income of -$37M, a net margin of -85.4%.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (1/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -7% a year, a 5-year average ROIC of 2%.
About Trinity Biotech
Trinity Biotech is listed in the US and classified in biotechnology: in vitro & in vivo diagnostic substances, IPO year 1992. Revenue went from $100M in 2015 to $44M in 2025, a decline of about 7.9% a year. It was profitable in 2 of the last 10 years in our data. Its share count fell by 26% over three years (buybacks).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Share count down over 3 years (buybacks)
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $44M | $62M | $57M | $63M | $81M | $102M | $90M | $97M | $99M | $100M |
| Net income | -$37M | -$32M | -$24M | -$41M | $875000 | -$6M | -$29M | -$22M | -$40M | -$101M |
| Free cash flow | -$12M | -$5M | -$12M | -$2M | $11M | $21M | $3M | -$299000 | $4M | $6M |
| EPS (diluted) | $-62.43 | $-39.09 | $-29.54 | $-50.43 | $1.08 | $-7.86 | $-35.56 | $-27.17 | $-49.52 | $-123.75 |
| Net margin | -85.4% | -51.6% | -42.3% | -65.6% | 1.1% | -6.3% | -32.0% | -22.8% | -40.6% | -101.0% |
| ROIC | — | — | — | — | 4.6% | 0.1% | -26.9% | -13.7% | -23.1% | -18.2% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Trinity Biotech pay a dividend?
Not currently.
Is Trinity Biotech a good stock to buy?
We do not give buy or sell advice. Trinity Biotech scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.